A carregar...
ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib
BACKGROUND: Osimertinib (AZD9291), a third generation mutation-selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (EGFR-TKI), is an approved drug for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations or those harboring resistant T790M mutation. Unfor...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7050394/ https://ncbi.nlm.nih.gov/pubmed/31821539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32655 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|